News Releases

November 2020

November 24, 2020 11/24/2020 Announcement of Making Nihon Pharmaceutical Co., Ltd. a Wholly-owned Subsidiary Through Simple Share Exchange

November 13, 2020 11/13/2020 Final Results from the Phase 3 HELP Study™ Open-Label Extension Support TAKHZYRO® (lanadelumab-flyo) Injection as a Long-term Preventive Treatment Option in Patients with Hereditary Angioedema

November 5, 2020 11/5/2020 Takeda Oncology Demonstrates Leadership in Hematologic Cancers at 62nd American Society of Hematology (ASH) Annual Meeting

October 2020

October 29, 2020 10/29/2020 Takeda Expands COVID-19 Vaccine Supply in Japan Through Partnership with Moderna and Government of Japan

October 29, 2020 10/29/2020 Notice of the Revised Forecast of Consolidated Financials for FY2020 (IFRS)

October 29, 2020 10/29/2020 Takeda FY2020 H1 Results Demonstrate Portfolio Resilience; Confirms Full-Year Management Guidance & Raises Forecasts for Free Cash Flow, Reported OP & Reported EPS

October 13, 2020 10/13/2020 Takeda Accelerates Digital Transformation with Accenture and AWS

October 12, 2020 10/12/2020 Safety and Efficacy of Subcutaneous Entyvio® (Vedolizumab) Sustained During Long-term Maintenance Therapy in Adults with Moderately to Severely Active Ulcerative Colitis

October 8, 2020 10/8/2020 First Patient Enrolled in NIH Phase 3 Trial to Evaluate Potential COVID-19 Hyperimmune Medicine